Bone Biologics CEO letter details $5.1M financing, plans for 30-patient NB1 trial in Australia by 2023

Bone Biologics Corp

Raised $5.1M gross in underwritten public offering of common stock and warrants for clinical trials and working capital.
Modified license agreement with UCLA TDG in May 2022 to defer diligence fees until first product sale.
Engaged MTF Biologics for DBM supply and a CDMO for recombinant protein manufacturing for NB1.
Expects to commence 30-patient pilot study in Australia in 2023 evaluating NB1 in lumbar interbody fusion.
NB1 addresses $3B global market for bone graft substitutes in spine fusion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.